Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
inactivated trivalent split-virus influenza vaccine
- Development stage
- Approved
- Lead developer
- Sanofi
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
The **inactivated trivalent split-virus influenza vaccine** is an injectable seasonal flu vaccine containing three components: two inactivated influenza A virus subtypes (H1N1 and H3N2) and one B/Victoria lineage virus. The "split-virus" formulation means the viruses are chemically disrupted to reduce reactogenicity while retaining immunogenic viral proteins. This type of flu shot does not contain live virus and cannot cause the flu. It works by inducing an immune response against hemagglutinin antigens from each included strain, providing protection against circulating seasonal strains that match the selected components[1][2][6]. The primary indication is prevention of seasonal influenza infection for individuals aged 6 months and older[2]. For the 2024–2025 season, all U.S.-approved injectable flu vaccines will be this trivalent formulation due to global disappearance of B/Yamagata lineage viruses[1][2].
- Brand names
- FluzoneFluarixAfluriaFluLavalFlucelvax
- Other names
- trivalent influenza vaccine, inactivatedTIV (trivalent inactivated vaccine)IIV3 (inactivated influenza vaccine, trivalent)split-virus flu shot (trivalent)
02
Targets
SA (Sialic acid)HA (Hemagglutinin)
Beyond the preview
Go deeper on inactivated trivalent split-virus influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inactivated trivalent split-virus influenza vaccine.